Press Release
Secures Government Funding from Korea Drug Development Fund (KDDF)
2021.11.05
- - AimedBio's innovative brain tumor therapeutic (P302) has been selected as a government project by the Korea Drug Development Fund (KDDF).
- - P302 is a first-in-class antibody-drug conjugate (ADC) targeting a brain tumor-specific fusion protein.
- - The P302 candidate has shown excellent anti-tumor efficacy in preclinical studies.
- - AimedBio leveraged patients' genetic and clinical data along with patient-derived materials throughout the antibody development process, raising expectations for effective outcomes in real-world patients.